Reviews Rosiglitazone Maleate


No reviews yet.

Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009




Avandia Drug Description
AVANDIA®
(rosiglitazone maleate) Tablets

WARNING
CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart failure in some patients [see WARNINGS AND PRECAUTIONS].
After initiation of AVANDIA, and after dose increases, observe patients
carefully for signs and symptoms of heart failure (including excessive,
rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop,
the heart failure should be managed according to current standards of care.
Furthermore, discontinuation or dose reduction of AVANDIA must be considered.

AVANDIA is not recommended in patients with symptomatic heart failure.
Initiation of AVANDIA in patients with established NYHA Class III or IV
heart failure is contraindicated. [See CONTRAINDICATIONS
and WARNINGS AND PRECAUTIONS.] A meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total
patients), most of which compared AVANDIA to placebo, showed AVANDIA to
be associated with an increased risk of myocardial ischemic events such
as angina or myocardial infarction. Three other studies (mean duration 41
months; 14,067 total patients), comparing AVANDIA to some other approved
oral antidiabetic agents or placebo, have not confirmed or excluded this
risk. In their entirety, the available data on the risk of myocardial ischemia
are inconclusive. [See WARNINGS AND PRECAUTIONS.]



DRUG DESCRIPTION



What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using rosiglitazone and call your doctor at once if you have any of these serious side effects:

feeling short of breath, even with mild exertion;
swelling or rapid weight gain;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
nausea, stomach...
Read All Potential Side Effects for Avandia »




AVANDIA (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily
by increasing insulin sensitivity. AVANDIA improves glycemic control while reducing
circulating insulin levels.
Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas,
the biguanides, or the alpha-glucosidase inhibitors.
Chemically, rosiglitazone maleate is (±)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,
(Z)-2-butenedioate (1:1) with a molecular weight of 473.52 (357.44 free base).
The molecule has a single chiral center and is present as a racemate. Due to
rapid interconversion, the enantiomers are functionally indistinguishable. The
structural formula of rosiglitazone maleate is:








The molecular formula is C18H19N3O3S•C4H4O4.
Rosiglitazone maleate is a white to off-white solid with a melting point range
of 122 to 123°C. The pKa values of rosiglitazone maleate are 6.8 and 6.1.
It is readily soluble in ethanol and a buffered aqueous solution with pH of
2.3; solubility decreases with increasing pH in the physiological range.
Each pentagonal film-coated TILTAB tablet contains rosiglitazone maleate equivalent
to rosiglitazone, 2 mg, 4 mg, or 8 mg, for oral administration. Inactive ingredients
are: Hypromellose 2910, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol 3000, sodium starch glycolate, titanium dioxide,
triacetin, and 1 or more of the following: Synthetic red and yellow iron oxides
and talc.Last reviewed on RxList: 2/6/2009





Other reviews about Rosiglitazone Maleate on wordpress

A Diabetes Outcome Progression Trial has shown reduced risk of monotherapy failure in people with type 2 diabetes
  by rognar
Results from ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial treatment with Avandia® (rosiglitazone maleate) reduced the risk of monotherapy failure in people with type 2 diabetes […]


Landmark Study Shows Avandia(R) (rosiglitazone Maleate) Is More Effective Than Metformin Or A Sulfonylurea In Long-Term Blood Sugar Control
  by rognar
Results from ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial treatment with Avandia(R) (rosiglitazone maleate) reduced the risk of monotherapy failure in people […]


Open access medicine: who needs the FDA or HC?
  by Corey Tomsons
What should we make of dinosaur publishers leading the charge against dangerous drugs? On Monday, GlaxoSmithKline received some bad news about Avandia, its drug for diabetes patients. According to […]


Smithkline Blocks Bland Avandaryl
  by kevinatoviolet
For May 11, 2007 Smithkline Beecham tabular a not use up sabotage indictment up Teva Pharmaceutical Industries alleging that the Teva’s deference in regard to ANDA in furtherance […]


Smithkline Blocks Bland Avandaryl
  by kevinatoviolet
For May 11, 2007 Smithkline Beecham tabular a not use up sabotage indictment up Teva Pharmaceutical Industries alleging that the Teva’s deference in regard to ANDA in furtherance […]


Too small to fail
  by Equalizer
What about the small guys. Where is the line for the mum and pa shops. the future prosperity of most countries depends less on the lumbering behemoths that have […]


AVANDIA® (rosiglitazone maleate) Tablets
  by kanlayanee
[caption id="" align="alignnone" width="215" caption="AVANDIA®"][/caption] AVANDIA® WARNING: CONGESTIVE HEART FAILURE AND MYOCARDIAL ISCHEMIA Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure in […]


Rosiglitazone goes on the RECORD, but is it a hit?
  by Larry Husten
A big new rosiglitazone trial, RECORD, found no increase in overall cardiovascular morbidity and mortality, the primary endpoint of the trial, but is unlikely to quiet the drug's […]


FDA MedWatch - November 2009 Drug Safety Labeling Changes
  by irbtipoftheweek
The MedWatch November 2009 Drug Safety Labeling Changes posting includes 44 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, […]


More bad news for Avandia (rosiglitazone)
  by Michael D. Shaw
If it weren't bad enough back in 2007, when Cleveland Clinic cardiologist Steven Nissen first suggested that the drug could cause heart attacks, now a new JAMA article […]



Other reviews about Rosiglitazone Maleate on web:

Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells ... Rosiglitazone - Wikipedia, the free encyclopedia


Learn about the prescription medication Avandia (Rosiglitazone Maleate), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Avandia (Rosiglitazone Maleate) Drug Information: Uses, Side ...


Comprehensive and trusted information about Rosiglitazone maleate - plus advice on 24,000 other FDA approved drugs and medications from Drugs.com. Rosiglitazone maleate patient advice including side effects


Learn about the prescription medication Avandamet (Rosiglitazone Maleate and Metformin HCl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Avandamet (Rosiglitazone Maleate and Metformin HCl) Drug ...


IMPORTANT SAFETY INFORMATION for AVANDIA ® (rosiglitazone maleate) AVANDIA can cause or worsen heart failure. If you have severe heart failure (very poor pumping ability of the ... Diabetes Medication and type 2 diabetes treatment important safety ...


Learn more about Rosiglitazone Maleate. Find the Web's best health guides, medical reports, news, videos and tools for Rosiglitazone Maleate. Share Rosiglitazone Maleate ... Rosiglitazone Maleate Overview - References, Advice, News, Videos ...


Rosiglitazone Maleate professional patient advice. Specific and up to date information about Rosiglitazone Maleate. Complete Rosiglitazone Maleate information from Drugs.com


rosiglitazone maleate Warning - High-alert drug! Avandia. Pharmacologic class: Thiazolidinedione. Therapeutic class: Hypoglycemic. Pregnancy risk category C rosiglitazone maleate - definition of rosiglitazone maleate in the ...


Find out about the science and chemistry of rosiglitazone maleate, Rosiglitazone (Avandia, Avandamet, Avandaryl, rosiglitazone maleate), see colourful images of Rosiglitazone and ... rosiglitazone maleate, What is rosiglitazone maleate? About its ...


Avandia (rosiglitazone) is a thiazolidinedione medication for the therapy of Type 2 diabetes. The US label for rosiglitazone has recently been revised to include combination therapy ... Diabetes Monitor - Rosiglitazone (avandia)





Featured Reviews

Reviews Alglucosidase Alfa

Myozyme Drug Description MYOZYME® (alglucosidase alfa) FOR INTRAVENOUS INFUSION ONLY WARNING RISK OF HYPERSENSITIVITY REACTIONS LIFE-THREATENING ANAPHYLACTIC REACTIONS, INCLUDING ANAPHYLACTIC SHOCK, HAVE BEEN OBSERVED IN PATIENTS...
Read More  |  Review This
Reviews Eflornithine

Vaniqa Drug Description VANIQA® (eflornithine hydrochloride) Cream, 13.9% For topical dermatological use only. Not for ophthalmic, oral or intravaginal use. DRUG DESCRIPTION What are the possible side effects of eflornithine...
Read More  |  Review This
Reviews Pepcid

Pepcid Drug Description PEPCID® (Famotidine) Tablets DRUG DESCRIPTION What are the possible side effects of famotidine, calcium, and magnesium (Dual Action Complete, Pepcid Complete)? Get emergency medical help if you have...
Read More  |  Review This
Reviews Methenamine, Salicylate, Methylene Blue, Benzoic Acid Atropine and Hyoscyamine

Prosed DS Drug Description Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) DRUG DESCRIPTION PROSED®/DS is a dark blue, round, sugar coated tablet for oral administration. Each...
Read More  |  Review This
Reviews Vibativ

Vibativ Drug Description VIBATIV (telavancin) for Injection, for Intravenous Use WARNING: FETAL RISK Women of childbearing potential should have a serum pregnancy test prior to administration of VIBATIV Avoid use of VIBATIV...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....